Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | PER2 | O15055 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29909547 | 0.90 | ABCG2 (0.41) | ABCG2MAPTPER2HCRTR1 | |
| SCHEMBL23577044 | 0.90 | ABCG2 (0.41) | ABCG2MAPTPER2HCRTR1 | |
| SCHEMBL30961002 | 0.88 | MAPT (0.35) | MAPTPOLB | |
| SCHEMBL23576806 | 0.88 | MAPT (0.35) | MAPTPOLB | |
| SCHEMBL23576915 | 0.85 | ABCG2 (0.40) | ABCG2MAPTPER2HCRTR1 | |
| SCHEMBL29909020 | 0.85 | ABCG2 (0.40) | ABCG2MAPTPER2HCRTR1 | |
| SCHEMBL23576867 | 0.84 | MAPT (0.32) | ABCG2MAPTPOLB | |
| SCHEMBL29909268 | 0.84 | MAPT (0.32) | ABCG2MAPTPOLB | |
| SCHEMBL23577132 | 0.84 | ABCG2 (0.43) | ABCG2MAPTHCRTR1 | |
| SCHEMBL23577019 | 0.84 | ABCG2 (0.43) | ABCG2MAPTPER2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118324767-A | Diacylglycerol kinase modulating compounds | 卡尔那生物科学株式会社 | 2024-07-12 | — | — | CN | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | ABCG2 4216/4885MAPT 4206/4885PER2 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.